{"id":745,"date":"2001-04-01T12:06:00","date_gmt":"2001-04-01T10:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin"},"modified":"2001-04-01T12:06:00","modified_gmt":"2001-04-01T10:06:00","slug":"nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/nochmals-hyperkinetisches-syndrom-und-methylphenidat-ritalin","title":{"rendered":"Nochmals: Hyperkinetisches Syndrom und Methylphenidat (Ritalin)"},"content":{"rendered":"<p>Zur Erg\u00e4nzung unseres Referats zur Therapie des Hyperkinetischen Syndroms mit Methylphenidat (AMB 2001, 35, 12) hat uns ein Leser auf eine aktuelle, alarmierende Arbeit aus G\u00f6ttingen hingewiesen (Moll, G.H., et al.: J. Child Adolesc. Psych. Pharmacol. 2001, 11, 15). In einem Tierexperiment wurde sehr jungen und postpubert\u00e4ren Ratten zwei Wochen lang Methylphenidat verabreicht. Es konnte [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zur Erg\u00e4nzung unseres Referats zur Therapie des Hyperkinetischen Syndroms mit Methylphenidat (AMB 2001, 35, 12) hat uns ein Leser auf eine aktuelle, alarmierende Arbeit aus G\u00f6ttingen hingewiesen (Moll, G.H., et al.: J. Child Adolesc. Psych. Pharmacol. 2001, 11, 15). In einem Tierexperiment wurde sehr jungen und postpubert\u00e4ren Ratten zwei Wochen lang Methylphenidat verabreicht. Es konnte [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[750,749,748,751,658,1919,747],"class_list":["post-745","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-adhs","tag-attention-deficit-hyperactivity-disorder","tag-aufmerksamkeitsdefizit-hyperaktivitaetssyndrom","tag-hyperkinetisches-syndrom","tag-methylphenidat","tag-mta-studie","tag-zappelphilipp-syndrom"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=745"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/745\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}